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Exome sequencing of 343 families, each with a single
child on the autism spectrum and at least one unaf-
fected sibling, reveal de novo small indels and point
substitutions, which come mostly from the paternal
line in an age-dependent manner. We do not see
significantly greater numbers of de novo missense
mutations in affected versus unaffected children,
but gene-disrupting mutations (nonsense, splice
site, and frame shifts) are twice as frequent, 59 to
28. Based on this differential and the number of
recurrent and total targets of gene disruption found
in our and similar studies, we estimate between 350
and 400 autism susceptibility genes. Many of the dis-
rupted genes in these studies are associated with
the fragile X protein, FMRP, reinforcing links between
autism and synaptic plasticity. We find FMRP-asso-
ciated genes are under greater purifying selection
than the remainder of genes and suggest they are
especially dosage-sensitive targets of cognitive
disorders.
INTRODUCTION
Genetics is a major contributor to autism spectrum disorders.
The genetic component can be transmitted or acquired through
de novo (‘‘new’’) mutation. Analysis of the de novomutations has
demonstrated a large number of potential autism target genes
(Gilman et al., 2011; Levy et al., 2011; Marshall et al., 2008; Pinto
et al., 2010; Sanders et al., 2011; Sebat et al., 2007). Previously
cited studies have focused on large-scale de novo copy number
events, either deletions or duplications. Because such events
typically span many genes, discerning which of the genes in
the target region, alone or in combination, contribute to thedisorder becomes a matter of educated guessing or network
analysis (Gilman et al., 2011). However, with high-throughput
DNA sequencing we can readily search for new mutation in
single genes by comparing children to both parents. Such muta-
tion is fairly common, on the order of a hundred new mutations
per child, with only a few—on the order of one per child—falling
in coding regions (Awadalla et al., 2010; Conrad et al., 2011).
Thus, candidate gene and exome sequencing, involving the
capture of designated coding regions of the genome, are effi-
cient ways to search for new gene mutations in families. Prelim-
inary attempts with these approaches, including studies of
autism, have already been published (O’Roak et al., 2011;
Schaaf et al., 2011; Vissers et al., 2010; Xu et al., 2011).
Our study is based on 343 families, a subset of the Simons
Simplex Collection. In each family, only a single child is on the
spectrum, and each has one or more normal siblings. This
collection is depleted of multiplex cases where transmission
genetics is expected to play a greater role (Fischbach and
Lord, 2010). It is enriched for higher-functioning probands. As
a result, the gender ratio among probands in this study is roughly
1 female per 6 males. Our focus was to determine first and fore-
most if the various types of new mutations would have different
incidence in affected children than in their sibling controls. Not all
types of pointmutations are equally likely to be disruptive of gene
function, and the contribution of the various types of events to
autism incidence could not be evaluated in the absence of
knowledge of relative rates, in affected and the sibling controls.
Hence, we performed our analysis on family ‘‘quads’’ rather
than trios. We rejected the idea that a comparative rate could
be obtained by studies of unrelated controls performed at other
sequencing centers or even at our own sequencing centers if
performed at separate times with ostensibly similar protocols.
We conclude that de novomutations disrupting gene function,
such as indels that cause frame shifts and point mutations that
affect splice sites or introduce stop codons, are statistically
more likely in children on the autistic spectrum than in their unaf-
fected siblings. In contrast, we see no statistically significant
signal from either missense or synonymous mutations. IncludingNeuron 74, 285–299, April 26, 2012 ª2012 Elsevier Inc. 285
Figure 1. Exome Sequencing Family and Individual Coverage
For each individual, the proportion of the exome covered in excess of 203
(dotted green line) is plotted horizontally. For each family, the proportion of the
exome jointly covered in excess of 203 (solid red line) or 403 (black circle and
blue ‘‘plus sign’’ designating sequencing center) in all members of that family is
also shown. The family data are ordered by the rank of their joint coverage in
excess of 203.
Table 1. Validation of De Novo Calls
Passes (Filter) Confirmed Falsified
SNVs (99/105 Successfully Tested)
No (SNV) 7 3
Yes (SNV) 89 0
Nonsense (22/24 Successfully Tested)
No (SNV) 1 0
Yes (SNV) 21 0
Indels (49/49 Successfully Tested)
No (SNV or indel) 0 1
Yes (SNV only) 1 0
Yes (Indel only) 9 0
Yes (SNV and indel) 38 0
Two filters were used for counting calls, an SNV and indel filter. We list all
calls tested and the number of successful tests, separated into de novo
SNVs (top) and indels (bottom). The middle subtable is the subset of
SNVs that created stop codons (nonsensemutations), which are included
in the overall number in the top subtable. Calls fell either within (‘‘Yes’’) or
outside (‘‘No’’) the thresholds of the filter (first column), and were either
confirmed or falsified as a de novo variants (second and third columns).
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now detect contribute collectively to about 16% of the cases
of simplex autism, undoubtedly an underestimate of the actual
contribution. We observe an unusual coincidence between the
list of genes with disruptive de novo mutations in children with
autism and the list of 842 gene products associated with
FMRP (Darnell et al., 2011), itself a target of mutation in 2%
of children with ASD. Within the parental gene pool there are
far fewer disruptive variants in FMRP-associated genes than
found in typical genes, suggestive of stringent purifying selection
acting on FMRP-associated genes.
RESULTS
Scope and Coverage
We report on the sequence and analysis of whole exomes
from 343 families, each comprising parents and at least two
offspring. No families with a member of questionable pedigree
were included. To maximize the efficiency and uniformity of
sequencing and capture we adopted a barcoding and pooling
strategy. We used the NimbleGen SeqCap EZ Exome v2.0
capture reagent (Experimental Procedures). The 36.0 Mb target
sequence consists almost entirely of coding exons. On average,
individuals had 78% of the target covered at R203 and 56%
atR403. Since ours is a family study, we define ‘‘joint coverage’’
at a base as the minimum coverage at that base in any individual
member of that family. On average, families had 71% joint
coverage at R203 and 45% at R403. Ninety-six percent of
families had fifty percent or greater of target jointly covered
atR203. Coverage is presented graphically in Figure 1.286 Neuron 74, 285–299, April 26, 2012 ª2012 Elsevier Inc.To improve detection of indels and mutations at potential
splice signals, our sequence analysis pipeline included 20 bp
flanking each end of the coding exons, bringing our ‘‘extended’’
target to 43.8Mb.We counted de novo events over the extended
region even though coverage was lower than over coding target.
Filters and Validation Testing
We used a new multinomial test to determine likelihood that
a mutation was de novo. We also used a chi-square test to
exclude loci that did not fit a simple germline model, and we
excluded sites that were polymorphic or noisy over the popula-
tion. We established thresholds for these tests and used addi-
tional microassembly criteria, comprising our filters for counting
candidate events. We sampled calls for experimental validation
testing to determine our false positive rate.
Because the vast majority of false positives originate from the
chance undersampling of one parental allele, wemade an empir-
ical choice of likelihood thresholds that diminished the frequency
with which known polymorphic loci in the population appeared
as ‘‘de novo’’ mutations in the children (see Figure S1 available
online). These thresholds define part of our ‘‘SNV filter.’’ For
each indel call, we also used de Bruijn graph microassembly
as a filter (Pevzner et al., 2001) of reads possibly covering candi-
date regions in each of the family members.
For validation testing, we designed barcoded primers from
the reference genome for each mutation examined, individually
PCR-amplified DNA from each family member for the locus,
pooled by family relation to the proband, made libraries and
sequenced pooled products (Experimental Procedures). Valida-
tion tests succeeded or failed, and if they succeeded, the results
either confirmed or falsified the calls. A summary of results is
found in Table 1, for SNVs and indels. The detailed results
(including counts) are in Tables S1 and S3. We validated in three
batches, each time blind to the gene or affected status. In the
Table 2. Summary of De Novo Single Nucleotide Variants (SNVs) in 343 SSC Families
403 (High)
Coverage All Loci
SNV Effect Proband Sibling Proband Sibling Proband F (29) Proband M (314) Sibling F (182) Sibling M (161) Both Total
Splice site 4 1 6 3 1 5 1 2 0 9
Nonsense 15 7 19 9 3 16 6 3 2 30
Missense 125 121 207 207 19 188 116 91 3 417
Synonymous 53 42 79 69 8 71 43 26 4 152
Promoter 0 1 1 1 0 1 0 1 0 2
UTR 5 7 8 9 0 8 3 6 0 17
Intron 34 35 59 64 5 54 38 26 1 124
Intergenic 0 2 1 2 0 1 2 0 0 3
Total 236 216 380 364 36 344 209 155 10 754
De novo SNVswere tabulated according to affected status, gender, and type of mutation. Data under ‘‘403 coverage’’ indicate variants in the subset of
the exome target region in which all members of a given family were covered by at least 40 sequence reads. The power to detect de novo variants
in children from this well-covered portion of the target is very high, and we found no bias in coverage between affected and unaffected children.
No significant difference was seen for missense mutations (125 in probands to 121 in unaffected siblings), but larger ratios of nonsense (15:7) and
splice site (4:1) mutations were observed in probands relative to unaffected siblings. When we expanded our set of calls to include every variant
that passed our thresholds (under ‘‘all loci’’; see Experimental Procedures), similar ratios were observed. Probands and unaffected siblings are further
subdivided based on gender: ‘‘proband F’’ indicates an affected female; ‘‘proband M’’ an affected male; ‘‘sibling F’’ an unaffected female; and ‘‘sibling
M’’ an unaffected male. In parentheses, we indicate the number of children with the corresponding affected status and gender. The ‘‘both’’ column
shows de novo SNVs that were shared by both siblings from the same family.
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random calls passing filter. In the other two batches, we focused
on indels and nonsense mutations. In all three batches, we
tested a few calls close to passing but excluded by our filters.
We sought to produce a list of autism candidates with as few
false positives as possible and to be able to make the strongest
statistical evaluation of the differential rates of de novo mutation
between affecteds and siblings. We confirmed all 137 calls
passing filters that we successfully tested. We subsequently
loosened some and tightened other criteria for indels (the ‘‘indel
filter’’) to capture more events, as described below.
De Novo SNV Rates
We first investigated de novo SNVs. We counted 754 candidate
de novo events passing our SNV filter (summarized in Table 2;
complete list with details in Table S1). The distribution of events
in families closely fit a Poisson model. Events were classified by
affected status, gender, location (within exon, splice site, intron,
50UTR, and 30UTR) and type of coding mutation (synonymous,
missense, or nonsense). The specific position of the mutation
and the resulting coding change, if any, are also listed. In all
cases examined, microassembly qualitatively validated the de
novo SNV calls. Every de novo SNV candidate that passed filter
and was successfully tested was confirmed present in the child
and absent in the parents (89/89; Table 1 and Table S1).
Because variation in the number of mutations detected could
be a function of variable sequence coverage in probands versus
siblings, we also determined counts of mutation equalized by
high coverage, assessing only regions where the joint coverage
was at least 403. At such high coverage, less than 5% of true
de novo SNVs would be missed (as judged by simulations). We
then determined the de novo SNV mutation rate by summing
the total number of de novo SNVs in these 403 joint regionsfrom all individual children, then dividing by the sumof base pairs
within these regions in these children. The rate was 2.0 * 108
(±109) per base pair, or about 120 mutations per diploid
genomeper generation (6 * 109 * 2 * 108), consistentwith a range
of estimates obtained by others (Awadalla et al., 2010; Conrad
et al., 2011).
Table 2 contains a summary of our findings. The number of de
novo SNVs only in probands versus the number only in their
siblings is not significantly different than expected from the null
hypothesis of equal rates between probands and siblings,
whether counting all SNVs (380 versus 364), synonymous (79
versus 69), or missense (207 versus 207). Ten de novo variants
occurred in both proband and sibling. The balance does not
change if we examine only regions of joint coverage R403.
Applying additional filters for amino acid substitutions (conserva-
tive versus nonconservative) or genes expressed in brain also
did not substantively change this conclusion (Table S1).
However, this study lacks the statistical power to reject the
hypothesis that missense or synonymous mutations make a
major contribution (see Discussion).
We did see a differential signal when comparing the numbers
of nonsense mutations (19 versus 9) and point mutations that
alter splice sites (6 versus 3). Such mutations could reasonably
be expected to disrupt protein function, and in the following
we refer to such mutations as ‘likely gene disruptions’ (LGD).
The LGD targets and the specifics of the mutations in the
affected population are listed in Table 3, and more details for
all children are provided in Table S2. The sum of LGDs caused
by point mutation was 25 in affecteds to 12 in siblings, with a
p value of 0.047 by the two-sided binomial test. Every nonsense
candidate that passed filter and was successfully tested was
confirmed present in the child and absent in the parents
(21/21; Tables 1 and S1).Neuron 74, 285–299, April 26, 2012 ª2012 Elsevier Inc. 287
Table 3. Likely Gene-Disrupting (LGD) Mutations in Affected Children
Family ID Gender Variant Effect Gene Amino Acid Position FMRP Target
12221 M sub(C/ T) N FAM91A1 72/839 Yes
12501 M sub(A/ T) N NRXN1 587/1,177 Yes
12645 M sub(C/ T) N ANK2 104/1,049 Yes
12764 F sub(C/ A) N NCKAP1 1,082/1,129 Yes
12840 M sub(C/ T) N ATP1B1 143/299 Yes
12867 F sub(G/ A) N TRIP12 35/1,723 Yes
13094 M sub(T/ A) N WDFY3 978/3,527 Yes
12683 M del(1) F KDM6B 192/1,683 Yes
12705 M ins(C) F DIP2C 657/1,557 Yes
12952 M del(1) F MLL5 1,066/1,859 Yes
13012 M ins(CTGGTCT) F DIP2A 608/1,568 Yes
13092 M ins(AGGTCAG) F LMTK3 307/1,490 Yes
13612 M del(4) F DST 3,268/5,172 Yes
12969 M ins(C) S MED13L 1,789/2,211 Yes
12409 M sub(G/ A) N LRP2 3,184/4,656 No
12463 M sub(C/ T) N UNC80 518/1,765 No
12653 M sub(C/ T) N KIAA0232 118/1,396 No
12669 M sub(C/ T) S RABGGTA UTR No
12792 M sub(C/ T) N ANO5 420/913 No
12840 M sub(C/ T) S TM4SF19 68/210 No
12864 F sub(C/ T) S SUV420H1 86/646 No
13010 M sub(G/ C) S TBC1D23 293/700 No
13042 M sub(G/ A) N THSD7A 879/1,658 No
13125 M sub(C/ T) N RAD21L1 54/557 No
13197 M sub(G/ T) N NR3C2 701/868 No
13234 M sub(G/ A) N CBX4 131/561 No
13349 M sub(G/ A) N NUAK1 433/662 No
13364 M sub(G/ A) N ECM2 182/678 No
13506 M sub(C/ A) N SCUBE2 80/1,000 No
13513 M sub(G/ A) S ZMYND11 239/455 No
13526 M sub(A/ G) S CACNA2D3 592/939 No
13670 F sub(C/ T) N NFIA 30/502 No
12323 M del(1) F PHF2 1,088/1,097 No
12652 M del(1) F SPATA13 127/1,278 No
12653 M ins(A) F DLL1 431/724 No
12773 M del(4) F PCDHA13 678/951 No
12826 F del(4) F TROVE2 253/539 No
12858 F del(1) F PAX5 111/392 No
12939 M del(2) F SLC25A39 104/352 No
12950 M del(4) F UBN2 1,063/1,348 No
13018 M del(1) F PCOLCE 101/450 No
13070 M del(2) F CTTNBP2 760/1,664 No
13096 M del(1) F GIMAP8 149/666 No
13162 M ins(A) F RIMS1 196/1,693 No
13168 F del(1) F MFRP 342/580 No
13176 F del(1) F ZFYVE26 397/2,540 No
13183 M ins(G) F BCL11A 265/836 No
13398 M ins(CGTCATCA) F POGZ 1,108/1,316 No
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Table 3. Continued
Family ID Gender Variant Effect Gene Amino Acid Position FMRP Target
13439 M ins(A) F CSTF2T 354/617 No
13471 M del(2) F FLG 147/4,062 No
13537 M del(4) S TUBGCP4 578/667 No
13548 F del(1) F GALNTL4 521/608 No
13552 M del(1) F DYRK1A 487/755 No
13585 M ins(G) F ACACB 114/2,459 No
13586 M ins(G) F TRIM17 274/478 No
13590 M ins(A) F MTHFS 147/147 No
13590 M del(1) F EFCAB5 848/857 No
13616 M ins(G) F ATP10D 1,001/1,427 No
13646 M del(5) F VCP 515/807 No
SNV and indel variants from affected children that are likely to disrupt the function of the corresponding proteins are listed. The ‘‘family ID’’ column
indicates the SSC ID of the relevant family. Under ‘‘gender,’’ M stands formales and F for females. The ‘‘variant’’ column shows detail for reconstructing
the haplotype around the de novo variant relative to the reference genome as follows: ‘‘sub(R/ A)’’ represents a substitution of the reference allele to
an alternative allele; ‘‘ins(seq)’’ indicates an insertion of the provided sequence ‘‘seq’’; and ‘‘del(N)’’ denotes a deletion of N nucleotides. Chromosomal
locations for events can be found in Table S2. Under ‘‘effect,’’ ‘‘N’’ stands for nonsense, ‘‘S’’ for splice site, and ‘‘F’’ for frame shift events. The ‘‘amino
acid position’’ column shows the position of the first incorrectly encoded amino acid (or nonsense codon) within the encoded protein/the length of the
protein. When a mutation affects multiple isoforms of a transcript, the earliest proportionate coordinate is given. ‘‘FMRP target’’ indicates whether the
corresponding gene’s RNA was found to physically associate with FMRP (Darnell et al., 2011). See ‘‘Recurrence and Overlaps with FMRP-Associated
Genes’’ in the Results as well as Tables 5 and 6 for additional details.
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Further support for the hypothesis that LGDs contribute to ASD
comes from counting small insertions or deletions (indels) within
coding regions. Small indels were ascertained using a simple
protocol. This protocol works best for indels less than six
base pairs: we surveyed all reads that required a gap to align
to the reference genome, and marked where the gap was
placed. After eliminating all gap positions that are common in
the population, we again used our SNV filter: multinomial
sampling to estimate the likelihood that a gap in the child was
not inherited from either parent, and used a chi-square test for
a germline model (Experimental Procedures). We set the same
thresholds as used for SNVs. Microassembly excluded ten
presumptive indel loci as inconsistent, failing either because of
low count for confirmatory reads, absence of an indel, or finding
the nonreference allele in a parent. For two loci, the sizes of
deletions were corrected by microassembly. We tested 49
candidate de novo indels, and all 39 that passed the SNV filter
were confirmed. Incidence of indels in families again followed
a Poisson model.
It was quite clear from validation testing that many candidate
indels excluded by the SNV filter were true positives. There
was clearly allele imbalance favoring the reference allele over
the indel in the exome sequencing, but this bias was absent in
the validation testing (Table S2). Because of the importance of
indels, we wished to establish an ‘‘indel filter’’ that diminished
false negatives, so we lowered our chi-square stringency
(from 104 to 109) and multinomial threshold (from 60 to 30).
To guard against false positives resulting from undersampling
the parents, we excluded any locus at which the variant allele
was seen fewer than six times in the child, or appeared even
once in the parents, and insisted on certain lower limits of
coverage, all of which was done without respect to affectedstatus (Experimental Procedures). Of the 49 tested loci, 47
passed this new filter and confirmed (Table 1).
With the indel filter, wedetected 53 indels in probands and32 in
siblings (pvalue=0.03).Of these,32 inprobandsand15 insiblings
caused frame shifts (p value = 0.02; see Table 4 for summary and
Table S3 for complete list). Frame shift mutations, like nonsense
and splice mutations, can cause severe disruption of coding
capacity and hence we classify them as LGDs. Threemore indels
(2 in probands and 1 in siblings) are likely to be LGDs, as they
either introduce stop codons or disrupt a splice site. It is likely
that even in-frame insertions or deletions are more disruptive
to a peptide than a mere substitution, and we refer later to an
interesting example, but we do not count them as LGDs.
All LGD targets are listed in Table 3, with further details in Table
S2. In summary, using our filters for SNVs and indels, we observe
59 LGDs in probands versus 28 in siblings (p value of 0.001).
Gender and Phenotype
The de novo LGD incidence by gender and status can be
summarized from Tables 2 and 4. We observe 9 de novo LGD
events in 29 females on the spectrum, and 50 in 314 males.
Although only marginally statistically significant (p value =
0.07), the higher incidence in females matches the higher inci-
dence of de novo CNVs seen in females on the spectrum (Levy
et al., 2011), and does not reflect a higher rate of de novo muta-
tions in females overall: we detected 12 in 182 female siblings
and 16 in 161 male siblings. We observed no significant differ-
ence with respect to verbal or nonverbal IQ, or overall severity
in children with or without detectable de novo LGDs.
Origin of Mutations
Our data are consistent with a paternal origin for variation of the
type we detect. From the original sequencing and validation ofNeuron 74, 285–299, April 26, 2012 ª2012 Elsevier Inc. 289
Table 4. Summary of De Novo Indels in 343 SSC Families
Indel Effect Proband Sibling Proband F Proband M Sibling F Sibling M Both Total
Splice site 2 0 0 2 0 0 0 2
Frame shift 32 15 5 27 4 11 0 47
Nonsense 0 1 0 0 1 0 0 1
No frame shift 7 7 0 7 3 4 0 14
UTR 2 1 0 2 1 0 0 3
Intron 10 8 0 10 4 4 1 19
Total 53 32 5 48 13 19 1 86
The detected de novo indels were tabulated based on affected status and gender and stratified by the effects the events are likely to have on the
corresponding genes. De novo indels that are likely to severely disrupt the encoded proteins—by causing frame shifts, destroying splice sites, or
introducing nonsense codons—are significantly more abundant in affected children than in unaffected siblings. See Table 2 for details of the column
headings.
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for some de novo mutations, i.e., those that were linked to a
polymorphism found in only one of the two parents. We found
that the father is more frequently the parent of origin than the
mother: 50/17 for SNVs and 6/1 for indels (Table S1), with
a combined p value of 105. Although this was previously
known for SNVs, or at least suspected (Conrad et al., 2011),
our results suggest it is true for small indels as well. Because
it is implausible that the origin of a parental haplotype should
influence its global mutation rate in the child, we conclude that
most of the de novo variants passing our filters originated in
the parent.
Parental age also appears to play a role in mutation rate,
further evidence of the parental origin of the mutations we
observe. We divided all the data of de novo SNV mutations
from the 403 joint family coverage into three bins nearly equal
in base pairs covered, separated by the age of the father at
child’s birth, and then counted de novo SNVs in all three bins.
The bins spanned fathers from 16.1 to 30.9 (mean of 27.3),
30.9 to 35.9 (mean of 33.4), and 35.9 to 58.0 (mean of 39.6) years
old. There was no significant difference in overall SNV rate
between probands and siblings; hence, we utilized both children.
Wemeasured the counts of de novomutation in the three bins as
136, 139, and 181, respectively. The hypothesis that the counts
for de novo SNVs in children with the youngest fathers and in
those with the oldest arose from equal mutation rates has a
p value of 0.013. Performing the same computation for mothers,
we compute a p value of 0.002.
Our de novo filters are biased against somatic mutation, as our
likelihood models are based on germline mutation. However,
there are a handful of loci where the evidence is consistent
with a somatic origin: diminished ratios of variant to reference
allele in the child both in the exome coverage and in the counts
from the PCR validation tests. Moreover, in one case where it
could be discerned, the maternal haplotype was seen in associ-
ation with both the variant and reference allele. All these exam-
ples, however, are also consistent with multiple copies of the
loci in question. Our de novo filters are also biased against
mosaicism in the blood of the parent. Nevertheless, we see
two examples where deep sequencing of the PCR test revealed
the presence of the variant in the parent: one SNV in mother
(1,308 counts of reference to 28 counts of the variant) and one290 Neuron 74, 285–299, April 26, 2012 ª2012 Elsevier Inc.indel from the father (15,399 to 79). Not surprisingly, neither
variant was observed in the parent in the sparser exome data.
Altogether, with the filters we use, the de novo events we
report are largely and perhaps almost entirely germline in origin
and this affects our assessment of the contribution of newmuta-
tion to autism.
Recurrence and Overlaps with FMRP-Associated Genes
We searched for recurrences and overlaps between the 59 LGD
target genes and other gene lists (Tables 3 and 5), including
genes struck by de novo missense or present in de novo CNVs
from previous studies. There are no recurrences among our
LGD targets (but see Discussion). Given the large number of
potential autism target genes, failure to observe overlap in this
small list is not surprising. There are two overlaps with the 72
most likely candidate genes from our previous CNV study:
NRXN1 and PHF2. The former is considered to be casual for
ASD (Ching et al., 2010). A few overlaps of the LGD targets
and targets of missense mutations were observed, two in
siblings and one in probands, but this is well within random
expectation.
By contrast, we saw unexpected overlap between the LGD
targets, CNV-derived autism candidate genes and the set of
842 FMRP-associated genes. This last set of genes corresponds
to mRNAs whose translation may be controlled by the fragile X
mental retardation gene product FMRP (Darnell et al., 2011).
Microsatellite expansion in the X-linked FMR1 gene is an estab-
lished cause of autism spectrum disorders. Significant overlap of
the 842 FMRP-associated genes with autism candidate genes
has been previously suggested (Darnell et al., 2011). 14 of our
59 LGD targets and 13 of 72 CNV target genes, with one in
common, overlap with the 842 FMRP-associated genes. We
calculate the p values to be 0.006 and 0.0004, respectively.
The first p value is calculated relative to the cumulative gene
length of FMRP-associated genes, whereas the second is
more related to gene number and is determined by simulation
(Experimental Procedures). Altogether, the observation of 26
genes (14 plus 13 minus one in common) out of 129 (59 plus 72
with two in common) overlapping with the 842 FMRP-associated
genes has a p value of <1013 (calculated on a per-gene basis).
In contrast, we see no significant overlap between FMRP-asso-
ciated genes with LGD targets from siblings (2 of 28) or with de
Table 5. Overlaps with FMRP-Associated Genes
Gene List Number FMRP Targets p Value
LGD in probands 59 14 0.006
CNV candidates 72 13 0.0004
LGD + CNV candidates 129 26 <1013
LGD in siblings 28 2 0.8
Missense in probands 207 22 0.9
Missense in siblings 207 30 0.1
The overlap of six different gene lists with the set of FMRP-associated
genes (Darnell et al., 2011) is shown. ‘‘LGD in probands’’ is the list of
genes affected by de novo LGDs in affected children; ‘‘CNV candidates’’
are the best gene candidates for ASD derived from de novo CNVs
analyzed in a previous study (Gilman et al., 2011); ‘‘LGD + CNV candi-
dates’’ is the union of the previous two categories; ‘‘LGD in siblings’’ is
the list of genes affected by de novo LGD in unaffected siblings; and
‘‘missense in probands’’ and ‘‘missense in siblings’’ are the lists of genes
affected by de novo missense variants in probands and unaffected
siblings, respectively. For each list, we show the total number of genes,
the number of genes that are associated with FMRP, and the p value
under the hypothesis that the overlap is random. See Experimental
Procedures for details of the p value computation.
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(30 of 207), all squarely within expectation given the size of the
FMRP-associated genes. All data on overlaps are summarized
in Table 5.
Absent Statistical Signal from Inheritance
This study lacks the power to discover small effects due to
inheritance (see Discussion). Nevertheless, we sought evidence
for large effects. From 686 parents, we enumerated all rare
synonymous, missense, nonsense, and splice site variants in
the parents, over a set of well-annotated genes (the set of
18,000 CCDS genes; Pruitt et al., 2009), and the intersection
of that set with candidate genes from previous CNV studies (Gil-
man et al., 2011; Levy et al., 2011), candidate genes from the
present study of de novo LGDs, and all FMRP-associated genes.
We considered only rare variants (defined as occurring only once
in the population), eliminating the polymorphic variants so that all
variants were on an equal footing. We then examined transmis-
sion to children, by affected status. We observed no statistically
significant transmission bias of either missense or LGDs
(nonsense plus splice variants) in any gene set to either probands
or siblings. There was, in fact, slightly lower transmission to the
affected population than to the siblings (Tables 6A and 6B).
None of these statements change if we look specifically at vari-
ants carried by the mother.
We examined as well the prevalence of compound heterozy-
gotes of rare LGD variants, where an offspring receives one
rare variant from each parent, and again we see no statistically
significant difference between probands and unaffected siblings
(Table 6C). In this case, however, there is a slight increase in the
number of compound heterozygotes of well-annotated genes in
probands compared to siblings (242 versus 224).
We specifically examined the possibility of compound hetero-
zygosity in offspring at loci hit by de novo LGDs, caused by
transmission of rare missense or LGD mutations. We observednine such events in probands and twelve in siblings, all but one
in each group a combination of the de novo LGD event and
a rare missense variant. Thus, there is no differential signal for
compound heterozygosity and no evidence that the de novo
event in the affected created a homozygous null.
Extreme Scarcity of LGDs in FMRP-Associated Genes
In the course of the abovework, we didmake an unexpected and
striking observation. The number of rare nonsense or splice
site variants over the FMRP-associated genes was much
lower than expected given the abundance of these variants
found in the CCDS genes (Table 7). We observed 2,192
rare nonsense variants in all genes, of which 55 fell within
FMRP-associated genes—a proportion of 0.025. We observed
63,080 synonymous rare variants with 7,051 falling within
FMRP-associated genes, a proportion of 11.18. The proportion
of all synonymous variants falling within in FMRP-associated
genes is roughly equal to the sum of the lengths of all FMRP-
associated genes divided by the sum of lengths of all well-
annotated genes. But the proportion of nonsense variants is
one-fourth of this cumulative length proportion. Using the
proportion of synonymous variants in CCDs as an unbiased
measure of opportunity for mutation between sets, we calculate
a p value of <1050 that the variants in FMRP-associated genes
are under the same degree of purifying selection as are the well-
annotated genes. Because FMRP-associated genes are on
average longer than the ‘‘typical’’ gene, we also computed the
proportion of genes in a given set that are ever observed with
a variant of a specified type. Qualitatively, we see the same
pattern. We see an even stronger decrease in variants that
disrupt splice sites within the FMRP-associated genes.
On the other hand, missense variants show a much less
extreme depletion in the FMRP-associated genes. This is con-
sistent with the view that while missense mutations can create
hypo- or hypermorphic alleles, they generally do not have the
impact of a disruption.
To understand better the significance of the results just
described, we examined the same statistics for two other genes
sets (Table 7). The first is a set of ‘‘disease genes,’’ 250 human
genes linked to known genetic disorders, the majority of which
are severely disabling (Feldman et al., 2008). In this set, variants
of all types behavedmuch the same as the synonymous variants.
The second set, ‘‘essential genes,’’ were the human orthologs of
1,700 murine genes. The murine genes were extracted by us
(combining automated andmanual methods) from a set of genes
annotated by the Jackson Laboratory, with annotations based
on breeding and transgenic experiments. The distribution of
variants in the ‘‘essential genes’’ closely resembles the distribu-
tion in the FMRP-associated genes.
DISCUSSION
From previous genetic studies, we expected that de novo muta-
tion plays a large role in autism incidence and introduces
variation that is short-lived in the human gene pool because
such variation is deleterious and highly penetrant. Sequencing
reveals the type and rates of small-scale mutation and pinpoints
the responsible gene targets more definitively than does copyNeuron 74, 285–299, April 26, 2012 ª2012 Elsevier Inc. 291
Table 6. Lack of Segregation Distortion
Gene Group Proband Sibling Proband & Sibling Neither Total
(A) Segregation of Rare Nonsense and Splice Site Variants
FMRP-associated 9 15 16 20 60
CNV candidates 3 1 3 0 7
De novo LGD 0 6 4 3 13
All of the above 12 22 20 23 77
All well-annotated 666 726 750 692 2,834
(B) Segregation of Rare Missense Variants
FMRP-associated 1,784 1,808 1,924 1,591 7,107
CNV candidates 99 99 116 108 422
De novo LGD 165 189 200 214 768
All of the above 1,973 2,017 2,168 1,833 7,991
All well-annotated 22,267 22,379 24,255 20,875 89,776
(C) Genes with Compound Heterozygosity (Rare Nonsense, Splice Site, and Missense)
FMRP-associated 28 31 59
CNV candidates 1 0 1
De novo LGD 4 3 7
All of the above 32 33 65
All well-annotated 242 224 466
Rare SNVs (those observed only once in the 686 parents in this study) are classified based on the children to whom they were transmitted: only to the
proband (‘‘proband’’); only to the unaffected sibling (‘‘sibling’’); to both children (‘‘proband & sibling’’) or to ‘‘neither’’ child.
(A) We classified rare variants by the gene they target. The segregation of several target groups of rare nonsense and splice site variants is indicated.
The ‘‘FMRP-associated’’ group is all variants that occur within the coding region of FMRP-associated genes; ‘‘CNV candidates’’ are defined as in Table
5; ‘‘de novo LGD’’ are the variants that occur in the 59 genes affected by de novo LGD in probands from this study; ‘‘all of the above’’ represents the
variants in at least one of the previous three target sets; and ‘‘all well-annotated’’ are variants that target well-annotated CCDS genes (Pruitt et al.,
2009).
(B) Segregation of rare missense variants categorized as in (A).
(C) Compound heterozygosity in probands and unaffected siblings. A compound heterozygote was defined as an instance in which a gene was
affected by two different rare variants—one from the mother and one from the father—in the same child. Genes are classified as in (A) and (B).
Neuron
De Novo Mutations, Autism, and FMRP-Associated Genesnumber or karyotypic analysis. Our study is a partial confirmation
of our expectations, provides sources and rates of some classes
of mutation, and strengthens the notion that a convergent set of
events might explain a good portion of autism: a class of
neuronal genes, defined empirically as FMRP-associated genes,
overlap significantly with autism target genes.
Our data set is the largest set of family exome data to be
reported so far, and it is derived from whole-blood DNA to
avoid the perils of immortalized cell lines. While we focused on
the role of de novomutation of different types in autistic spectrum
disorders, we have looked at additional questions related to new
mutation. We project overall rates of de novo mutation to be 120
per diploid genome per birth. Most small-scale de novomutation
comes from fathers, and is related to parental age. Per event (and
probably enmasse), missensemutations have far less impact on
the individual than do gene-disrupting mutations such as
nonsense, splice variants, and frame shifts. This is evident both
in overall differential in de novo mutations, but also from the
effects of purifying selection on sets of genes (Table 7).
Differential Signal from De Novo Missense
and Gene-Disrupting Mutations
Missense mutation should contribute to autism to some degree,
as gene function can be severely altered by single-amino-acid292 Neuron 74, 285–299, April 26, 2012 ª2012 Elsevier Inc.substitutions. However, we see no statistical evidence in our
work for the hypothesis that de novo missense mutations
contribute to autism. The number of de novo missense events
we observe is not greater in probands than in siblings. Moreover,
the ratio of numbers of missense mutations in probands to
siblings is not significantly different than the observed ratio of
numbers of synonymous mutations. Even when we filter for
genes expressed in brain, count missense mutations that cause
nonconservative amino acid changes, or count missense muta-
tions at positions conserved among vertebrates (Table S1,
columns BA–BJ), we see no statistical evidence for contribution
from this type of mutation. This is also true when we look for
overlap of de novo missense mutations with FMRP-associated
genes (Table 5). The lack of signal is not attributable to the
type of population we study, as we observe de novo copy
number imbalance of the expected magnitude in this very
same population (Levy et al., 2011; Sanders et al., 2011). But
given the size of the population and background mutation rate,
we are unable to find signal in the present study. A simple power
calculation indicates that we cannot rule out confidently even
a 20% contribution to autism from de novo missense mutation.
Despite these caveats, it is worth considering that de novo
mutation causing merely amino acid substitution may only rarely
create a dominant allele of strong effect.
Table 7. Incidence of Rare SNVs in the Parental Gene Pool
CCDS (18,168)
FMRP-Associated Genes
(790 in CCDS) Disease Genes (244 in CCDS) Essential Genes (1,672 in CCDS)
Effect Number Number Percent Ratio to Syn. Number Percent Ratio to Syn. Number Percent Ratio to Syn.
(A) Per Position
Missense 104,637 8,573 8.19 0.73 2,023 1.93 0.97 10,874 10.39 0.84
Nonsense 2,192 55 2.51 0.22 38 1.73 0.87 109 4.97 0.40
Splice site 1042 19 1.82 0.16 15 1.44 0.72 55 5.28 0.42
Synonymous 63,080 7,051 11.18 1.00 1,260 2.00 1.00 7,849 12.44 1.00
(B) Per Gene
Missense 16,232 755 4.65 0.91 221 1.36 0.96 1,509 9.30 0.96
Nonsense 1,887 44 2.33 0.46 34 1.80 1.26 95 5.03 0.52
Splice site 980 17 1.73 0.34 13 1.33 0.93 49 5.00 0.52
Synonymous 15,160 776 5.12 1.00 216 1.42 1.00 1,464 9.66 1.00
(A) Rare SNVs (defined as in Table 6) were classified according to their predicted mutational effect and whether they fell within four different sets of
genes. The mutational consequences of these variants have been determined using well-annotated CCDS gene models (Pruitt et al., 2009), first
column. ‘‘FMRP-associated’’ is the list of 842 FMRP-associated genes; ‘‘disease’’ is the list of 256 positionally cloned human disease genes (Feldman
et al., 2008), and ‘‘essential’’ is the list of 1,750 human orthologs of mouse genes that have been associated with lethality in the Mouse Genome
Database (Blake et al., 2011). The numbers in parentheses next to each gene set label show the numbers of genes from each category that are found
among the well-annotated CCDS set. For each mutational effect and for each gene set, the ‘‘number’’ column indicates how many variants occur in
that set, the ‘‘percent’’ column shows the percentage of all variants with that effect that fall within the gene set, and the ‘‘ratio to syn’’ column shows
the percentage normalized by the percent for the synonymous variants. Nonsense (2.51%) and splice site (1.82%) variants were substantially
underrepresented among FMRP-associated genes when compared to the percent of synonymous variants (11.18%).
(B) The ‘‘number’’ column refers to the number of genes in the given set affected by rare SNVs of the given mutational effect. The percent of these,
and the normalized percent, as defined in (A) above, are also shown.
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that are likely to disrupt gene function. In contrast to de novo
missense mutation, we do get signal from de novo mutations
likely to severely disrupt coding: mutations at splice sites,
nonsense mutations, and small indels, particularly indels that
cause frame shifts. We observe 59 likely gene disruptions
(LGD) in affected and 28 in siblings, a ratio of two to one.
We note that girls on the autistic spectrum have a higher rate
(9/29) than boys (50/314), a bias we have previously noted for
de novo CNV events. The total contribution from LGD mutations
can be estimated as 31 events in 343 families (59 events in
probands minus 28 events in siblings), or roughly 10% of
affected children.
Germline Origin: Rates, Parental Age, and Paternal
Variation
We observed de novo point mutations in children at the rate ex-
pected from other studies (Awadalla et al., 2010; Conrad et al.,
2011), about 120 point mutations per genome per generation.
We observe that the frequency of de novomutation is dependent
on parental age, and know this with a high degree of statistical
certainty. This observation is in keeping with, and potentially
explains, other studies that have shown increased incidence of
certain genetic disorders in the progeny of older parents,
including ASD (Saha et al., 2009).
From sequencing adjacent linked polymorphisms in children
and parents, we infer that on the order of 3/4 of new point
mutations (50 of 67) derive from the father’s germline. Although
we have less data, this conclusion holds as well for de novo small
indels (6 of 7). These data confirm the paternal line is the mainsource for these types of new human variation. The data also
indicate that the majority of the de novo calls in this study are
not somatic in origin, but occur prior to conception. We infer
this by assuming that after zygote formation, the mother’s and
father’s genomes are equally vulnerable to subsequent somatic
mutation. By contrast, a previous study indicated that for de
novo copy number variation both parents contribute almost
equally (Sanders et al., 2011).
We observe very few cases where two siblings share the
same de novo mutation, about one for every fifty occurrences,
suggesting that the parent is rarely a broad mosaic. However,
this conclusion could be an ascertainment bias, because our
operational identification of ‘‘de novo’’ precludes observing the
mutation in the parent at levels higher than expected from
sequencing error. As presented, we do observe some evidence
of parental mosaicism, and this is a subject of ongoing scrutiny
using enhanced statistical modeling and validation.
Total Contribution from De Novo Mutation
Finding the correct contribution from each genetic mechanism
is critical for understanding the nature of the factors causing
autistic spectrum disorders. Adding the 6% differential for
large-scale de novo copy number mutation previously observed
(Levy et al., 2011; Sanders et al., 2011) to the 10% differential
for LGDs, we reach a total differential of 16% between affected
children and siblings. This is far less than our predictions, based
onmodeling the AGRE population (Zhao et al., 2007), that causal
de novo mutations would occur in about 50% of the SSC. This
gap could be attributable to having modeled a more severely
affected population. The SSC is skewed to higher functioningNeuron 74, 285–299, April 26, 2012 ª2012 Elsevier Inc. 293
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2010), so there may be more borderline cases in that collection
than in the AGRE collection (male to female ratio of 3:1), from
which we built our model (Zhao et al., 2007).
But our differential must underestimate the contribution from
de novo events. First, we use extremely stringent criteria meant
to eliminate false positives, and we fail to detect many true posi-
tives as a consequence. Second, even among thedenovo events
we do observe, we may be missing gene-disruptive events, for
example, mutations outside the consensus that disrupt splicing
and in-frame indels that disrupt the spacing of the peptide back-
bone. It would not be unlikely to miss even a 5% differential from
de novo missense mutation in a study of this size, given the high
background rate of neutral missense mutation. Third, our
coverage of the genome is incomplete. Some of this arises by
chance, and some is systematic due to the exome capture
reagents or errors in the reference genome. Fourth, large classes
of mutations are eliminated by our filters, such as those that orig-
inate in a parent who is a mosaic, and in children who suffer
somatic mutation early after zygote formation. Fifth, there are
biases in correctly mapping reads covering regions of the
genome that are highly rearranged in the child. Sixth, we have
not implemented tools that can reliably detect large indels and
rearrangements. Our present tool is efficient only for small indels,
less than seven base pairs. Seventh, an entire class of events
involving repetitive elements is presently unexplored by us
becausewe currently demand that reads have uniquemappings.
Eighth, we make calls from only coding regions and thus are not
able to assess noncoding events that might affect RNA expres-
sion or processing. From all these presently hidden sources,
the contribution of de novomutation could easily double ormore.
While there is still a gap between the incidence of de novo
gene disrupting events and our expectations from population
analysis—especially in males—this gap may yet be filled by
deeper coverage, more refined genomic tools, and whole-
genome sequencing. Interpretation of a richer data set will
undoubtedly require a greater understanding of biology, such
as the role for noncoding RNAs and how transcript expression
and processing are controlled. By contrast, the differential
incidence of de novo mutation in females is very strong, and
from CNV and exome sequencing data, runs at nearly twice
the differential as in males.
Transmission Genetics and Gene Dosage
We find almost no evidence of a role for transmission genetics.
We do not think the present study of only 343 families would
display statistical evidence for any of the plausible models of
contribution from transmission. Such studies will require greater
power, and previous larger copy number studies of the SSC
have found such evidence (Levy et al., 2011). There is, however,
a weak signal from the increased ratio of compound heterozy-
gotes of rare coding variants in probands to siblings (242 versus
224). This would be consistent with a 5% contribution from
this genetic mechanism, but is also consistent with virtually no
contribution (p value = 0.4). We can virtually rule out that such
events are contributory in more than 20% of children on the
spectrum. Fortunately, even a modestly larger study will resolve
the strength of contribution from this source.294 Neuron 74, 285–299, April 26, 2012 ª2012 Elsevier Inc.We do not find evidence of compound heterozygosity at the
vastmajority of loci where one allele was hit by a disruptivemuta-
tion. These events are thus likely to have high impact by altering
gene dosage, although we cannot rule out at present that the
mutant allele acts by dominant interference.
Individual Vulnerability to New Mutation
Conceptually, any individual of a given genetic lineage has
a ‘‘vulnerability’’ to a disorder caused by new mutation in that
lineage. We can speak of the ‘‘naive genetic lineage’’ of the
zygote as that which is inherited from the grandparents before
the action of any mutation acquired during passage through
the parental germline. We then define the number of individual
vulnerability genes as the number of genes which if disrupted
(either in the parental germline or by early somatic mutation
after the zygote is formed) will result in the development of the
disorder. The size of individual vulnerability is not the same as
the target size of autism genes because the former depends
on genetic background and future history. Children do not
necessarily have the same set of vulnerability genes. The
average individual vulnerability over a population can be
measured from the ratio of number of de novo LGD events in
probands and siblings, as follows.
We will solve for the general case. Assume the rate for a given
mutation class in unaffecteds is R, and the rate in probands is
AR. In a population of size P, roughly RPmutations of that class
will occur, neglecting the small surplus coming from the small
number of affected individuals. The number of affected individ-
uals will be P / N, where 1 / N is the incidence in the population.
Thus, ARP / N mutations of the class will be found in affecteds.
RP / N of these will be present by chance and not contributory,
whereas (A 1)RP / N events are contributory. Thus the propor-
tion of all de novo mutations in a population of size P that








S is the probability that a de novomutation of the particular class
will contribute to the condition, andS is a function only ofA andN.
If each of G total genes had a uniform probability of being a
target for a de novo mutation, and T was the mean number of
vulnerability genes per affected, and mutations of the class





Now, for LGD in autism, taking N = 150, A = 2 and G = 25,000,
we can compute the average individual vulnerability per child
as 167 genes.
This of course is only a crude argument because genes do not
have a uniformmutation rate, and not every LGD in a target gene
will have complete penetrance. Nevertheless we make note that
the size of individual vulnerability appears to be roughly half the
target size of all autism genes (see last section of the Discussion).
Candidate Genes
Other than NRXN1, we did not see any genes among the de-
tected de novo LGD targets that had been conclusively linked
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(encoding a cortactin-binding protein) was suggested as a
potential candidate for the autism susceptibility locus (AUTS1)
at 7q31 (Cheung et al., 2001). We now provide evidence, based
on a de novo 2 bp frame shift deletion, that mutations in
CTTNBP2may cause ASD. In addition, a number of other candi-
dates stood out as being potentially causal due to a combination
of provocative expression patterns, known roles in human
disease and suggestive mouse mutant phenotypes. Among
these were RIMS1, a Ras superfamily member necessary
for presynaptic long-term potentiation (Castillo et al., 2002).
A targeted Rims1 mutation in the mouse leads to increased
postsynaptic density and impaired associative learning as well
as memory and cognition deficits (Powell et al., 2004; Schoch
et al., 2002), and the frame shift allele we found may lead
to a similarly severe condition. Another intriguing candidate
was the serine/threonine-specific protein kinase DYRK1A,
which is located within the Down syndrome critical region of
chromosome 21 and believed to underlie at least some of the
pathogenesis of Down syndrome as a consequence of increased
dosage. Several reports of likely inactivating mutations in
DYRK1A result in symptoms including developmental delay,
behavioral problems, impaired speech and mental retardation
(Møller et al., 2008; van Bon et al., 2011), and a heterozygous
knockout in the mouse also led to developmental delay and
increased neuronal densities (Fotaki et al., 2002). Truncating
mutations in ZFYVE26 (encoding a zinc finger protein) are known
to cause autosomal recessive spastic paraplegia-15, consisting
of lower limb spasticity, cognitive deterioration, axonal neurop-
athy and white matter abnormalities (Hanein et al., 2008). It is
possible that a heterozygous truncating mutation such as the
de novo frame shift allele found in our study might cause a less
severe version of this condition resulting in an ASD diagnosis.
Other de novo mutations of interest were a 4 bp deletion in
DST (encoding the basement membrane glycoprotein dystonin),
which is associated with FMRP (Darnell et al., 2011) and
produces a neurodegeneration phenotype when inactivated in
themouse, and a nonsensemutation in ANK2 (an ankyrin protein
involved in synaptic stability [Koch et al., 2008]). A nonsense
mutation inUNC80 has been linked to control of ‘‘slow’’ neuronal
excitability (Lu et al., 2010).
We also note that thirteen of the 59 LGD candidates appear
to be involved in either transcription regulation or chromatin
remodeling. Among the latter are three proteins involved in
epigenetic modification of histones: ASH1L, a histone H3/H4
methyltransferase that activates transcription (Gregory et al.,
2007); KDM6B, a histone H3 demethylase implicated in multiple
developmental processes (Swigut and Wysocka, 2007), and
MLL5, a histone H3 methyltranserase involved in cell lineage
determination (Fujiki et al., 2009). These three are also FMRP-
associated genes.
Relation of Candidate Genes to FMRP-Associated
Genes
Fragile X syndrome (FXS) is one of the most common genetic
causes of intellectual disability, with up to 90% of affected
children exhibiting autistic symptoms. This has suggested over-
laying recent understanding of FXS biology onto candidate ASDgenes (Darnell et al., 2011). The FMR1 gene is expressed in
neurons and controls the translation of many products. A set
of 842 FMRP-associated genes has been enumerated by cross-
linking, immunoprecipitation, and high-throughput sequencing
(HITS-CLIP), and this set was previously noted to overlap candi-
date genes from de novo CNVs (Darnell et al., 2011). Hence, we
checked the list of FMRP-associated genes with our lists of
59 LGD targets and 72 most likely autism candidate genes
from de novo CNVs, and found a remarkable overlap: 14 and
13 with one in common, thus 26/129, with a p value of 1013
determined on a per gene basis (842 FMRP-associated genes
out of 25,000 genes). This overlap is remarkable because half
of the LGD targets should not be ASD related, and probably
a similar number of the most likely CNV genes. We found no
unusual overlap between the FMRP-associated genes and de
novo LGD targets in unaffected siblings, or between FMRP-
associated genes and de novo missense targets in either
affected or unaffected children.
As a follow-up to this striking observation, we searched for de
novo mutations in targets upstream of FMR1 and found an
intriguing one:GRM5. It is hit by a deletion that is not a frame shift
but removes a single amino acid and causes an additional
substitution at the deletion site.GRM5 encodesmGluR5, a gluta-
mate receptor coupled to a G protein (Bear et al., 2004). Defects
in mGluR5 compensate for some of the fragile X symptoms in
mice (Do¨len et al., 2007), and mGluR5 antagonists are currently
in clinical trial (Jacquemont et al., 2011).
Lack of LGD Variants in FMRP-Associated Genes
in the Population
FMRP has been proposed to inhibit protein translation of certain
critical transcripts involved in neuroplasticity, the coordinated
sensitization or desensitization of neurons in response to activity.
Hence, it is reasonable to suppose that the physiological mech-
anisms modulated by FMRP depend on protein concentration,
which in turn might be sensitive to gene dosage.
Direct support for this idea comes from surveying the entire
parental population for carriers of potentially disruptive gene
variants. Using a well-annotated set of human genes as controls,
FMRP-associated genes are strongly depleted for mutations
that affect splicing or introduce stop codons. The statistical
significance of the numbers is striking, whether computed as
a rate relative to synonymous mutations or on a per gene basis.
We see a similar depletion of LGDs in a set of human orthologs
of mouse genes that are enriched for essential genes but we
do not see this extreme depletion in a set of 250 genes linked
to known disabling genetic disorders. This difference may reflect
the strong purifying selection in humans against disruptions of
even a single allele of genes in this set. The hypothesis that the
majority of the FMRP-associated genes are dosage-sensitive
requires a more thorough analysis.
Mediators of Neuroplasticity inCognitive andBehavioral
Disorders
FMRP may act as one component of a central regulator of
synaptic plasticity, among others such as TSC2 (Darnell et al.,
2011; Auerbach et al., 2011). Impairment of its function, or the
components it regulates, or other regulators like it, mightNeuron 74, 285–299, April 26, 2012 ª2012 Elsevier Inc. 295
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shows these components may be dosage-sensitive targets in
autism. By extension, neuroplasticity, the hallmark function of
our nervous system that enables learning and adaption in
responses to stimulation, might have a general vulnerability to
mutation affecting gene dosage. Mediators of neuroplasticity
could be searched profitably for involvement in other cognitive
disorders.
Three Recent Studies
While our manuscript has been under review, three similar but
smaller studies were published: Neale et al., 2012 (N), O’Roak
et al., 2012 (O), and Sanders et al., 2012 (S). Each reported
exome sequence of about 200 family trios (N) or a mixture of trios
and quads (O and S). (O) and (S) report of families from the SSC
collection. None of the SSC samples overlapped with ours, but
unlike our random selection from the SSC, (O) was enriched for
females and severely affected children, and (S) was enriched
for families with > 1 normal sibling.
We summarize the findings in these papers that overlap ours:
more de novo point mutation in children with older parents
(all three), higher incidence in female than male probands (N),
paternal origin of most de novo mutations (O), an elevated ratio
(R2:1) of de novo gene disruptions in probands versus siblings
(S), no segregation distortion of rare polymorphisms from
parents (S), and a de novo point mutation rate of about 2.0 3
108 per base pair per generation (O and N). The single point
of slight disagreement concerns differential signal from de
novo missense mutation, which is marginal in (S) and not evident
in our data.
All groups report de novo gene disruptions (nonsense, splice,
and frame shifts) in probands, 18 in (N), 33 in (O), and 17 in (S),
for a total of 68. With the 59 from this study, a total of 127 hits
in probands have been found. Judging from our two-fold
differential rate in probands and siblings, we expect that at least
half of the 127 hits, about 65, are causal. Five genes were hit
twice. DYRK1A and POGZ are the new recurrences found by
combining our data with theirs. With our projected differential
between probands and sibling controls, these five genes that
are recurrent targets of de novo disruptions in probands are
almost certainly autism targets.
From our estimate of 65 causal gene disruptions and 5 recur-
rent gene targets, we project that the total number of dosage-
sensitive targets for autism is about 370 genes. We made
a similar estimate from de novo CNVs (Levy et al., 2011; see
Recurrence Analysis in Supplemental Experimental Procedures).
With this target size, and an expected 50% increase in rate of
discovery of de novo gene disruptions, similar studies of all
2800 SSC families should yield about 116 autism genes, thereby
identifying unequivocally about a third of the dosage-sensitive
gene targets.
The other groups did not report on the number of gene disrup-
tions occurring within the FMRP-associated genes. However,
15 of their 68 do hit these genes, a rate similar to what we
observed (14 of 59). Combining data, we now compute a p value
of 23 104 that this is mere coincidence. We project that nearly
half of autism target genes will be among the list of FMRP-asso-
ciated genes.296 Neuron 74, 285–299, April 26, 2012 ª2012 Elsevier Inc.EXPERIMENTAL PROCEDURES
Sample Collection
The Simons Simplex Collection (SSC) was assembled at 13 clinical centers,
accompanied by detailed and standardized phenotypic analysis. The institu-
tional review board of Cold Spring Harbor Laboratory approved this study,
and written informed consent from all subjects was obtained by SFARI.
Families with single probands, usually with unaffected siblings, were preferen-
tially recruited, and families with two probands were specifically excluded
(Fischbach and Lord, 2010). Bloods, drawn from parents and children
(affected and unaffected) were sent to the Rutgers University Cell and DNA
Repository (RUCDR) for DNA preparation. DNAs from 357 families (of 2,800
total in the collection) were used in this study for exome capture, sequencing,
and analysis. We used family sets of four individuals (father, mother, proband,
one unaffected sibling), referred to as ‘‘quads,’’ for all analyses in this study. Of
a starting total of 357 families, 173 were sent to the Genome Center at
Washington University (St. Louis, MO, USA) for exome capture and
sequencing; the remaining 184 were processed and sequenced at CSHL.
Three hundred forty-three families met coverage targets and passed gender,
pedigree, and sample integrity checks. Only those 343 families were consid-
ered in this report.
Exome Capture and Sequencing
Sequence capture was performed with NimbleGen SeqCap EZ Exome v2.0,
representing 36.0 Mb (approximately 300,000 exons) of the human genome
(hg19 build). We used standard protocols from NimbleGen (http://www.
nimblegen.com/products/lit/06403921001.pdf) with minor changes as per
published procedures (Hodges et al., 2009). Wemade additional modifications
as follows: 1 mg genomic DNAwas sonicated from each individual on a Covaris
E210 instrument (300 bp setting). Barcoded sequencing adapters were ligated
prior to capture to allow multiplexing of samples. A total of 96 different barco-
des were used; eight pools of twelve 8 nt barcodes each were created, and
one pool applied to each individual. This allowed us to sequence two families
(or 8 individuals) per sequencing lane. Following adaptor ligation, DNAs were
purified using 0.4 volumes of AMPure XP beads (Agencourt). DNAs were then
amplified for 8 cycles, and family sets (250 ng of DNA from each of 4 individ-
uals) were pooled and captured in the same reaction. Postcapture DNAs
were amplified for 15 cycles. Samples were quantitated after pre- and post-
capture PCR on the Agilent 2100 Bioanalyzer and diluted to 10 nM concentra-
tion prior to loading on sequencing flow cells. All sequencing was performed
on the Illumina HiSeq 2000 platform using paired-end 100 bp reads.
Validation
Candidate de novo variants were confirmed via a PCR and pooled high-
throughput sequencing procedure. For each event, primers were designed
using BatchPrimer3 (http://probes.pw.usda.gov/batchprimer/) according to
the following conditions: primers were 18–27 nt in length; amplicons were
300 bp; and the optimal Tm of the primers was 62C. The specificity of
each primer pair was assessed by BLAST against the human genome refer-
ence sequence (hg19 build). Primers were synthesized by Integrated DNA
Technologies (Coralville, IA, USA). For each of the target mutations (and for
only those families of children with the candidate de novo event), we con-
ducted four discrete PCR reactions (corresponding to the four family
members). After PCR, we created four product pools, one each for fathers,
mothers, probands and unaffected siblings, by combining the respective
products from different families. A single adenosine nucleotide was added
to the 30 end of PCR amplicons, followed by ligation of barcoded adapters
to each pool of 30-adenylated products. All pools were then combined and
enriched by 8 cycles of PCR. The resulting libraries of pooled validation prod-
ucts were quantitated (Agilent 2100 Bioanalyzer), loaded onto a MiSeq instru-
ment (Illumina), and analyzed by 150 bp paired-end reads. After deconvolution
of barcodes and mapping, reads were binned according to genomic location
and family member.
Computational Pipeline
Additional detail for each of the following paragraphs is found in the
Supplemental Information.
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We used the standard Illumina analysis pipeline (CASAVA) with custom
additions to deconvolute and trim our barcodes. We used BWA for alignment
(Li and Durbin, 2009) and GATK (McKenna et al., 2010) for refinements. SNV
and indel variant callers were based on the same core statistical model, the
Multinomial Model. We established databases of parental genotypes and all
allele read counts. Filter thresholds were the parameter settings for the multi-
nomial model. Local microassembly was added for further computational
validation.
We used two databases of gene models to assign mutational effects to
the identified de novo and inherited variants: the UCSC genes and the
CCDS sets of gene models, both downloaded from the UCSC Genome
Bioinformatics website (http://genome.ucsc.edu). The UCSC database was
more comprehensive but with potentially more noise, as opposed to the
CCDS that contained fewer but high-confidence gene models. Variants that
altered the 2 bp at the beginning or end of each intron were classified as
‘‘splice sites.’’
Multinomial Model
Our approach has been to genotype the members of a family all at the same
time, not individually, thus using all the family information and the exploiting
the uniformity of data that results from barcoding and pooled capture and
sequencing. In our computations, we use a simple error model in which the
allele in a read may be incorrectly called once per hundred times, and is
assumed independent for family member and position. The genotypes are
assigned based on the likelihood of the 81 possible states given a two allele
standard autosomal model, and fewer states when assessing the X chromo-
some. The de novo score (denovoScr) is based on an aggregation of the poste-
rior probabilities of the states which obey Mendelian segregation rules, and
is scaled as the negative log10. This score is used for one filter threshold.
A p value pc2E is also determined at every locus for the best state from a ‘‘good-
ness of fit’’ c2 test, based on an analytical multinomial distribution with 8
outcomes. The p value is used as another filter threshold.
Counting SNVs/Indels
For the de novo andMendelian SNV genotype calls, we only considered reads
that had been mapped with quality of at least 30 (Li and Durbin, 2009) and that
had not been flagged as PCR duplicates, and we counted only bases whose
recalibrated base quality was at least 20. The reference allele was set to the
nucleotide found in the reference genome, and the alternative allele was set
to the non-reference allele with the largest count.
For every read that BWA aligned with a gap, we generated one or more
candidate indel variants. A candidate indel is characterized with a position in
the reference genome coordinates, whether an insertion or a deletion, as
well as a length. We then counted the number of reads that supported a partic-
ular candidate indel variant and the number of reads that overlapped the
candidate position but did not support the same variant.
Filters: De Novo SNV Genotype Calls
We only considered de novo candidates with denvoScr > = 60 and pc2E > =
0.0001. The choice of 60 was dictated by a desire to keep false positives to
a minimum, and we determined it by computing the proportion of polymorphic
loci that appear as de novo candidates as a function of the score (Figure S1).
We introduced additional filter criteria to suppress false positives: we only
accepted candidates for which the parents were homozygous for the refer-
ence allele and that were not at polymorphic or noisy positions. This comprises
our ‘‘SNV filter.’’ Further details are found in the Supplemental Information.
Filters: De Novo Indel Genotype Calls
We applied two filters for the indel caller. For the ‘‘SNV filter’’ applied to indels,
we used the same settings for denovoScr and pc2E , but to control for polymor-
phism and noise, we used a simple approach of filtering candidates for which
the same indel was seen in more than 200 reads from the entire data set.
For the ‘‘Indel filter,’’ we substantially relaxed the denovoScr and pc2E require-
ments to 30 and 109 but insisted on having clean counts: parents were not
allowed to have any reads with the candidate indel and were required to
have at least 15 reads supporting the reference allele. At least one of the chil-
dren had to have 6 or more reads with the candidate allele comprising at least
5% of her reads. We also strengthened the population requirement by filtering
positions with more than 100 reads containing the candidate indel in the entire
data set outside of the family.Microassembly Validation Pipeline
Most de novo SNV mutations and all indels passing the filters were tested
using the microassembly pipeline. The basic steps of the microassembly
method are as described by Pevzner et al., 2001 (using de Bruijn graphs).
Reads were decomposed into overlapping k-mers, and directed edges were
added between k-mers that were consecutive within any read. All reads
mapping within 100 bp of the candidate mutation, as well as reads that did
not map to the assembly but were indicated to have been within 100 bp of
the candidate mutation by their mates, were included. Paths were partitioned
by family member.
Significance Tests for Overlap with FMRP-Associated Genes
Likely Gene Disruptors (LGD)
Under the assumption that SNV and indel variants occur randomly across
coding regions, larger genes will be more likely to accumulate higher numbers
of such variants. In addition, (1) the proportion of a gene that is included in the
design of the capture reagents and (2) nonuniform capture coverage across
the target will influence the expected numbers of variants of a gene or group
of genes. To address these issues, we based our expectation of number of
variants per gene (or group of genes) on the distribution of observed rare
synonymous mutations in the 686 parents. Specifically, 7,051 of the 63,080
(or 11.18%) of all rare synonymous SNVs fell within the FMRP-associated
genes (Table 6). We set 11.18% as the expected proportion for LGD variants
in FMRP-associated genes and used a binomial test to assign p values to
the observed overlap between FMRP-associated genes and LGD variants in
probands and their unaffected siblings and assigned p values for the overlap
with missense variants similarly (Table 5).
CNV Candidates
CNV candidate genes (Gilman et al., 2011) were obtained through a greedy
optimization procedure that selected the most interconnected (in the context
of a whole genome molecular network) subset of genes from the set of
genes affected by a de novo deletion or duplication in autistic probands.
Themolecular network utilized cumulative expert and experimental knowledge
that was heavily biased toward what had been studied such that it was difficult
to accurately quantify. To measure the significance of the observed overlap
between the 72 CNV candidates and the FMRP-associated genes, we
performed a permutation test: random CNV regions were selected, preserving
the number of genes as in the real CNVs, the 72 most interconnected genes
were identified using the greedy optimization (allowing at most 2 genes per
CNV region), and the overlap with FMRP-associated genes was recorded
(Gilman et al., 2011). We repeated this procedure 10,000 times and built an
empirical distribution for the number of FMRP-associated genes if the CNVs
were taken as random. Only 4 of 10,000 permutations produced an overlap
equal to or larger than the observed 13 FMRP-associated genes.
SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure, three tables, and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.neuron.2012.04.009.
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